CytomX Therapeutics CTMX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -29.4%-47.4pp | 18.1%+24.5pp | -6.4%+184pp | -190.6%+120pp | |
| Net margin | -22.8%-45.9pp | 23.1%— | —— | -186.8%+124pp | |
| EBITDA margin | -29.2%-47.4pp | 18.2%+24.5pp | -6.3%+184pp | -190.3%+120pp | |
| Free cash flow margin | -99.5%-36.8pp | -62.7%-6.5pp | -56.2%+155pp | -211.7%+112pp | |
| Returns | |||||
| Return on assets | -12.8%-32.5pp | 19.8%— | —— | -33.1%+0.1pp | |
| Efficiency | |||||
| Asset turnover | 0.6×-0.3× | 0.9×+0.4× | 0.4×+0.3× | 0.2×+0.1× | |
| Liquidity | |||||
| Current ratio | 3.1×+1.8× | 1.3×+0.1× | 1.2×-0.4× | 1.6×-2.4× | |
| Quick ratio | 3.1×+1.8× | 1.3×+0.1× | 1.2×-0.4× | 1.6×-2.4× | |
| Cash ratio | 0.3×-0.2× | 0.4×+0.3× | 0.1×-1.2× | 1.3×-1.4× | |
| Leverage | |||||
| Debt-to-equity | 0×— | —— | —— | —— | |
| Debt-to-assets | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $0.72+13,393% | -$0.01+99.2% | -$0.64+50.7% | -$1.30-18,534% | |
| Valuation | |||||
| Market capitalization | $711.89M+94.8% | $80.61M-22.4% | $103.83M-1.8% | $105.73M-62.6% | |
| Enterprise value | $685.92M+110% | $51.94M-48.4% | $100.64M+244% | -$69.86M-171% | |
| Price / sales | 20×+17.6× | 0.6×-0.4× | 1×-1.0× | 2×-5.6× | |
| Price / book | 2.2×-12.4× | —— | —— | —— | |
| EV / sales | 19.3×+17.1× | 0.4×-0.6× | 1×+2.3× | -1.3×-4.0× | |
| Free cash flow yield | -11.3%+11.0pp | -107.4%-52.6pp | -54.8%+51.6pp | -106.4%-63.7pp | |
| Earnings yield | -8.3%-19.7pp | 39.5%— | —— | -93.9%-52.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CytomX Therapeutics's ratios come from?
- Every ratio is computed from CytomX Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
